PTCT

#2809
PTC Therapeutics, Inc. - Common Stock
71.8 8 USD
+1.17%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
71.60
72.15
Year Range
44.17
87.50
Daily Change
+1.17%
Monthly Change
+10.94%
6 month change
-13.60%
Year Change
+46.96%
Previous Close
71.0 5
Open
71.6 3
Low
71.6 0
High
72.1 5
Volume
62
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 596.24 M
  • Employee 991
  • Founded 1998
  • CEO Matthew B. Klein
  • Website www.ptcbio.com
  • Headquarter Delaware, United States
  • FIGI BBG000QT15P7
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
9.76
Price to sales ratio
3.88

PTC Therapeutics, Inc. - Common Stock

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.

News